FDA
-
-
-
-
-
-
-
Jones Trading on Praxis Precision Medicines Inc. (PRAX): 'one step closer to becoming a commercial-stage company'
-
-
-
-
-
-
-
Raymond James Starts Praxis Precision Medicines Inc. (PRAX) at Strong Buy, 'Bears Sound Smart, but Bulls Make Money'
-
-
-
-
-
-
-
Praxis Precision Medicines hires epilepsy expert Dr. Orrin Devinsky as head of clinical strategy
-
-
-
-
-
-
-
Guggenheim on Praxis Precision Medicines (PRAX): one of our Top Picks for 2026
-
-
-
-
-
-
-
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
-
-
-
-
-
-
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $304 at Needham
-
-
-
-
-
-
-
TD Cowen on Praxis Precision Medicines Inc. (PRAX): 'Sensitivity Analyses Robust & Supportive Of Topline'
-
324,747 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

